冠昊生物：安润可降解泪小管栓目前业务处于起步阶段

Core Viewpoint - The company is actively developing a new generation of dry eye treatment products, specifically the Anrun® biodegradable tear duct plug, which is designed for temporary tear duct occlusion in patients undergoing corneal refractive surgery and cataract surgery. The market potential for this product is currently being assessed as the business is in its early stages, indicating some uncertainty in future operations [2]. Group 1 - The Anrun® biodegradable tear duct plug is a product developed by the company's subsidiary, Juming Biotechnology [2]. - The product targets temporary tear duct occlusion treatment for patients with surgery-induced dry eye conditions [2]. - The company acknowledges that its business is in the initial phase, which brings a level of uncertainty regarding future operational performance [2]. Group 2 - The company aims to seize market opportunities and enhance product competitiveness moving forward [2].